Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients
Portfolio Pulse from Vandana Singh
Dexcom's Stelo Glucose Biosensor System, an FDA-approved over-the-counter continuous glucose monitor, is now available for purchase. It targets Type 2 diabetes patients not using insulin, offering personalized glucose insights without fingersticks. Dexcom collaborates with Amazon for deliveries, and users can pay using flexible spending accounts.
August 26, 2024 | 3:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dexcom's Stelo device, an OTC continuous glucose monitor, is now available for purchase. This product targets Type 2 diabetes patients not using insulin, providing affordable glucose monitoring solutions.
The launch of the Stelo device as an OTC product expands Dexcom's market reach to a large population of Type 2 diabetes patients not using insulin. This could drive sales and positively impact DXCM's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
Abbott Laboratories' new OTC CGM systems, Lingo and Libre Rio, were approved by the FDA in June. These products compete with Dexcom's Stelo in the glucose monitoring market.
Abbott's new CGM systems, Lingo and Libre Rio, are direct competitors to Dexcom's Stelo. While this news highlights competition, it doesn't directly impact ABT's stock in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 50